WASHINGTON, Jan 11 (Reuters) - Altus Pharmaceuticals Inc., a biopharmaceutical company focused on the treatment of chronic gastrointestinal and metabolic disorders, on Wednesday set its planned initial public offering at 6 million shares at an estimated price of $14 to $16 each.